Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MLYCD | O95822 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | PHGDH | O43175 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806573 | 0.95 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL17886723 | 0.88 | HPGD (0.67) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL25018488 | 0.87 | MLYCD (0.62) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL17886717 | 0.86 | L3MBTL3 (0.73) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL10720943 | 0.86 | PHGDH (0.81) | ALDH1A1SMN1; SMN2HTTKMT2AHPGD | |
| SCHEMBL2627051 | 0.85 | HSP90AA1 (0.61) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL14461333 | 0.84 | MLYCD (0.59) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL270727 | 0.84 | MEN1 (0.90) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4406614 | 0.84 | MEN1 (0.96) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL31499366 | 0.83 | EPHX2 (0.79) | SMN1; SMN2MEN1KMT2AHPGDMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | ALDH1A1 1635/4885SMN1; SMN2 2264/4885HTT 2990/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | ALDH1A1 1973/4885SMN1; SMN2 1976/4885HTT 4257/4885 |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | ALDH1A1 4805/4885SMN1; SMN2 4471/4885HTT 3256/4885 |
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | PCK1, SLC5A1, PFKFB1 | ALDH1A1 345/4885SMN1; SMN2 2333/4885HTT 4879/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885SMN1; SMN2 4746/4885HTT 3657/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | ALDH1A1 3279/4885SMN1; SMN2 4806/4885HTT 2429/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ALDH1A1 2661/4885SMN1; SMN2 536/4885HTT 750/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | ALDH1A1 3235/4885SMN1; SMN2 4746/4885HTT 3657/4885 |
| US-20090111800-A1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 109/4885SMN1; SMN2 4355/4885HTT 3966/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | ALDH1A1 1270/4885SMN1; SMN2 4251/4885HTT 2807/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | ALDH1A1 1929/4885SMN1; SMN2 1840/4885HTT 3220/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885SMN1; SMN2 4779/4885HTT 1153/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885SMN1; SMN2 4779/4885HTT 1153/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | ALDH1A1 804/4885SMN1; SMN2 4242/4885HTT 2013/4885 |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885SMN1; SMN2 4779/4885HTT 1153/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | ALDH1A1 2661/4885SMN1; SMN2 536/4885HTT 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.